Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Depot Extension in Pediatric Hypothalamic Obesity
NCT00171613Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Primary completion
- Oct 2005
- Modality
- Peptides
01
Overview
Phase 4, open-label, single-arm trial of octreotide in hypothalamic obesity (HO), sponsored by Novartis. Primary endpoint: Change from baseline in BMI at 6 months. Started Feb 2005; status: completed.
02
Drugs
octreotide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT00171613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171613.